2023
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
Rodler E, Sharma P, Barlow W, Gralow J, Puhalla S, Anders C, Goldstein L, Tripathy D, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Pusztai L, Hayes D, Hortobagyi G. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology 2023, 24: 162-174. PMID: 36623515, PMCID: PMC9924094, DOI: 10.1016/s1470-2045(22)00739-2.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerMedian progression-free survivalProgression-free survivalMetastatic breast cancerMetastatic triple-negative breast cancerGermline BRCA1/2Phase 2 trialVeliparib groupPlacebo groupPlatinum-based chemotherapyBreast cancerHomologous recombination deficiencyAdverse eventsPARP inhibitorsEligible patientsMetastatic diseaseEastern Cooperative Oncology Group performance statusBRCA mutation-associated breast cancerInvestigator-assessed progression-free survivalTreatment-related adverse eventsRecurrent triple-negative breast cancerAcademic clinical sitesAddition of veliparibCommon grade 3Lines of chemotherapy
2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncology 2020, 6: 1598-1605. PMID: 32880602, PMCID: PMC7489368, DOI: 10.1001/jamaoncol.2020.3524.Peer-Reviewed Original ResearchConceptsProgression-free survivalObjective response rateTumor-infiltrating lymphocytesTumor mutational burdenPD-L1 statusOverall survivalHormonal therapyPrior linesPD-L1Clinical trialsMedian numberDay 1Cell death ligand 1 (PD-L1) inhibitorsERBB2-negative metastatic breast cancerMedian progression-free survivalDeath ligand 1 (PD-L1) inhibitorsEnd pointCause adverse eventsEfficacy of eribulinHormone receptor positiveMulticenter phase 2PD-L1 22C3Treatment-related deathsLines of chemotherapyPrimary end point
2019
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Tolaney S, Barroso-Sousa R, Keenan T, Trippa L, Hu J, Luis I, Wulf G, Spring L, Sinclair N, Andrews C, Pittenger J, Richardson E, Dillon D, Lin N, Overmoyer B, Partridge A, VanAllen E, Mittendorf E, Winer E, Krop I. Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal Of Clinical Oncology 2019, 37: 1004-1004. DOI: 10.1200/jco.2019.37.15_suppl.1004.Peer-Reviewed Original ResearchProgression-free survivalObjective response rateNeutrophil-lymphocyte ratioTumor-infiltrating lymphocytesTumor mutation burdenOverall survivalPrior linesMedian progression-free survivalCheckpoint inhibitor monotherapyMedian prior linesKey secondary endpointLines of chemotherapyPD-L1 statusTime of progressionChemotherapy 1Eligible patientsHormonal therapyPrimary endpointProtocol therapySecondary endpointsInhibitor monotherapyArm BMedian ageArm ATherapy 2Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
Murphy A, Walker R, Lutz E, Parkinson R, Ahuja N, Zheng L, Jaffee E, Azad N. Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.4_suppl.591.Peer-Reviewed Original ResearchArm BArm AColorectal cancerAdvanced CRC patientsMedian treatment cycleMMR-deficient CRCMMR-proficient tumorsLines of chemotherapyAdvanced colorectal cancerPre-treatment biopsiesPost-treatment biopsiesPredictors of responseEpigenetic therapyCTCAE v4.0CRC patientsImmune checkpointsMedian ageProficient tumorsRepeat biopsySingle institutionDisease progressionArm C.Arm CGrade 3Patients
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastasesMicrowave Thermal Ablation in an Unusual Case of Malignant and Locally Advanced Rare Tumor of Pancreas in ASA IV Old Male Patient and Literature Review
D’Amico F, Finotti M, Di Renzo C, Pasquale A, Bertacco A, Caturegli G, Gondolesi GE, Cillo U. Microwave Thermal Ablation in an Unusual Case of Malignant and Locally Advanced Rare Tumor of Pancreas in ASA IV Old Male Patient and Literature Review. Case Reports In Gastrointestinal Medicine 2018, 2018: 6064912. PMID: 29850295, PMCID: PMC5925082, DOI: 10.1155/2018/6064912.Peer-Reviewed Original ResearchIntraductal papillary mucinous neoplasmSystemic disease statusPapillary mucinous neoplasmComputed tomographyPancreatic tumorsPancreatic intraductal papillary mucinous tumorsDisease statusPancreatic intraductal papillary mucinous neoplasmsIntraductal papillary mucinous tumorBiliary tree dilatationWorsening of jaundiceLines of chemotherapyStaging CT scanHead of pancreasRare primary neoplasmOld male patientKinds of tumorsCardiovascular complicationsPalliative surgeryMultimodality treatmentOverall survivalPalliative treatmentComplete responseMale patientsPrimary neoplasms
2015
Outpatient palliative care encounters in stage IV lung cancer care: An institutional review.
Rizk S, Prsic E, Rafelson W, Reagan J, Taber A. Outpatient palliative care encounters in stage IV lung cancer care: An institutional review. Journal Of Clinical Oncology 2015, 33: 128-128. DOI: 10.1200/jco.2015.33.29_suppl.128.Peer-Reviewed Original ResearchNon-small cell lung cancerStandard oncologic careStage IV non-small cell lung cancerPalliative carePC interventionsOverall survivalSick visitsRetrospective analysisPC groupLung cancer carePalliative care encountersUtilization of emergencyLines of chemotherapyOutpatient palliative careReceipt of chemotherapyEmergency department visitsCell lung cancerCommon practice patternsStudy inclusion criteriaSignificant differencesPC encountersHospice referralDepartment visitsMultidisciplinary clinicOncologic care
2011
Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J. Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2011, 6: 790-795. PMID: 21325974, DOI: 10.1097/jto.0b013e3182103b51.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntimetabolites, AntineoplasticCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDrug CombinationsFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingOxonic AcidPrognosisSalvage TherapySurvival RateTegafurConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerOverall response rateLung cancerAdvanced stage non-small cell lung cancerCommon treatment-related side effectsStage non-small cell lung cancerResponse rateMulticenter phase II studyTreatment-related side effectsDisease control rateLines of chemotherapyPhase II studyPrimary end pointSecond-line therapyPhase II trialProgression-free survivalNon-Asian populationsOral fluoropyrimidineOral SStable diseaseII trialII studyHistologic subtype
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply